Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9517014 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4ERAB9AMAPTTDP1 | |
| SCHEMBL11180589 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KDM4ERAB9AMAPTTDP1 | |
| SCHEMBL19995811 | 0.77 | ALDH1A1 (0.39) | ALDH1A1KDM4ERAB9AMAPTTDP1 | |
| SCHEMBL6251693 | 0.75 | RAB9A (0.47) | ALDH1A1KDM4ERAB9AMAPTMEN1 | |
| SCHEMBL29408052 | 0.73 | ALDH1A1 (0.41) | ALDH1A1KDM4ERAB9AMAPTTDP1 | |
| SCHEMBL10272042 | 0.73 | KDM4E (0.50) | ALDH1A1KDM4ERAB9AMAPTTDP1 | |
| SCHEMBL23657574 | 0.72 | RAB9A (0.63) | ALDH1A1KDM4ERAB9AMAPTMEN1 | |
| SCHEMBL3537734 | 0.71 | ALDH1A1 (0.35) | ALDH1A1KDM4ERAB9AMAPTTDP1 | |
| SCHEMBL3899982 | 0.70 | PDE10A (0.52) | ALDH1A1KDM4ERAB9AMAPTTDP1 | |
| SCHEMBL6840370 | 0.70 | ALDH1A1 (0.60) | ALDH1A1KDM4ERAB9AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | disclosed |
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2006-03-16 | — | — | US | disclosed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| US-4588732-A | Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors | CIBA-GEIGY CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0068386-B1 | SUBSTITUTED IMIDAZO(1,5-A)PYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS | CIBA-GEIGY AG (CH) | 1985-12-18 | — | — | EP | disclosed |
| US-4470986-A | ISCHEMIA, SHOCK, THROMBOSIS | CIBA-GEIGY CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0114573-A1 | Imidazo(1,5-a)pyridine derivatives | CIBA-GEIGY AG (CH) | 1984-08-01 | — | — | EP | disclosed |
| EP-0114572-A1 | Substituted imidazo(1,5-a)pyridines | CIBA-GEIGY AG (CH) | 1984-08-01 | — | — | EP | disclosed |
| US-4444775-A | ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-04-24 | — | — | US | disclosed |
| EP-0068386-A1 | Substituted imidazo(1,5-a)pyridines, process for their preparation and pharmaceutical preparations containing these compounds | CIBA-GEIGY AG (CH) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | CYP11B1, CYP17A1, CYP27A1 | ALDH1A1 208/4885KDM4E 2057/4885RAB9A 2645/4885 |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | CYP11B1, CYP27A1, CYP17A1 | ALDH1A1 218/4885KDM4E 2005/4885RAB9A 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.